HVIVO SERVICES LIMITED

The FDA has granted Orphan Drug Designation to POLB 001, an oral p38 MAP kinase inhibitor designed to prevent or treat cytokine release syndrome (CRS) induced by T-cell engager bispecific antibodies.

ILiAD Biotechnologies and hVIVO have signed a Letter of Intent to conduct a pivotal Phase 3 human challenge trial for ILiAD's BPZE1 pertussis vaccine.

hLAB, a subsidiary of hVIVO, has signed a £2.7 million contract with a US-based biotechnology firm to support a Phase 2 influenza drug trial.

hVIVO has successfully completed a pilot characterization study for its human metapneumovirus (hMPV) strain A2 challenge agent, demonstrating proof-of-concept.

• hVIVO's COVID-19 characterization trial identifies blood-based biomarkers distinguishing early and late-stage respiratory viral infections, including SARS-CoV-2. • The identified biomarkers could enhance the diagnosis and management of early and late-stage infections, potentially before PCR confirmation. • The study, published in Nature Communications, underscores the value of human challenge trials in understanding immune responses and accelerating drug development. • hVIVO's research supports the development of next-generation treatments for COVID-19 and other respiratory viruses, addressing limitations of current vaccines.

Inhalon Biopharma is collaborating with hVIVO to conduct a Phase 2a human challenge trial for its antiviral candidate, IN-002, targeting respiratory syncytial virus (RSV).

Enanta Pharmaceuticals' EDP-323 demonstrated significant viral load reduction in a Phase 2a human challenge trial for Respiratory Syncytial Virus (RSV).